Matthew R Reetz

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE The US Food and Drug Administration issued a boxed warning on all products containing a long-acting β-agonist (LABA) in March 2006, after the findings from a trial suggested an increased risk for death in patients treated with salmeterol monotherapy. Almost nothing is known about the impact of this warning on LABA prescribing patterns or on(More)
  • 1